Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nevirapine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Nevirapine | EXPERIMENTAL | - |
| Viramune® | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Nevirapine | DRUG | Nevirapine 400mg PR tablet |
| Viramune® | DRUG | Viramune® 400 mg Retardtabletten |
Inclusion Criteria: 1. Signed and dated written informed consent prior to admission to the study 2. HIV1 infected males or females of 18 to 65 years, nonsmoker (use of cannabis may be accepted) 3. Body weight ≥ 50.0 kg and BMI ≥ 18.0 and ≤ 32.0 kg/m2 4. Absence of clinically significant history of ...
Nevirapine is a small molecule drug being developed by Teva Pharmaceutical Industries Limited for HIV-1 infection. It is in Phase 1 clinical development. The program includes one completed Phase 1 trial conducted in the United Kingdom.
Nevirapine is being evaluated for the treatment of HIV-1 infection. It is an investigational small molecule in Phase 1 development, and its use in HIV-1 has been studied in a completed Phase 1 trial. It is not described as approved for this indication.
Nevirapine is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program for this HIV-1 candidate.
Nevirapine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The completed study was an active-controlled Phase 1 trial conducted in the United Kingdom.
Nevirapine has been studied in one completed Phase 1 trial, NCT02202005, titled Multiple Dose BE Study With Nevirapine 400mg PR Tablets. The trial enrolled 46 participants in the United Kingdom and included an active control. It was not randomized or double-blind.